Drug Profile
Research programme: caspase inhibitors - New World Laboratories
Alternative Names: NWL 149; NWL 154; NWL 53Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator New World Laboratories
- Class Anti-inflammatories; Antidementias; Antineoplastics; Antiparkinsonians; Peptidomimetics; Vascular disorder therapies
- Mechanism of Action Caspase 1 inhibitors; Caspase 4 inhibitors; Caspase 6 inhibitors; Caspase-3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Brain injuries; Cancer; Huntington's disease; Inflammation; Multiple sclerosis; Myocardial infarction; Parkinson's disease; Spinal cord injuries; Stroke
Most Recent Events
- 22 Sep 2023 Preclinical development in Alzheimer's disease, Brain injuries, Cancer, Huntington's disease, Multiple sclerosis, Stroke, Spinal cord injuries, Parkinson's disease, Myocardial infarction and Inflammation is still ongoing in Canada (New World Laboratories pipeline, September 2023)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada
- 28 Dec 2020 No recent reports of development identified for preclinical development in Brain injuries in Canada